

CLINICAL TRIAL

IRIS II - NCT02670980



Low vision

Compensation for blindness with the Intelligent Retinal Implant System (IRIS V2) in patients with retinal dystrophy

Rare Eye Disease concerned by the trial :
retinal dystrophy

Status of the trial : completed
Orphan drug recognition : N/A

Inclusion criteria : Patient is 25 years or older at the date of enrolment, has a confirmed diagnosis of retinitis pigmentosa, choroideremia or cone-rod dystrophy, has a visual acuity of logMAR 2.3 or worse in both the eyes as determined by a Square Grating scale, has functional ganglion cells and optic nerve activity, has a memory of former useful form vision, understands and accepts the obligation to present for all schedule follow-up visits

Exclusion criteria : [click here to see detailed criteria](#)



Inclusion
opening date : 08/01/2016



Inclusion closing
date (previsonal) : 28/04/2019

Children



Adults



Within ERN-EYE members



Principal location of the trial :

CHNO des XV XX
29 Rue Manin
75019 Paris
France

[Contact details](#)




Principal investigator name :

Dr Yannick Le Mer



Other investigators :

**MAOLYA - Centre national de référence
des maladies rares**
Service Ophtalmologie
Hôpital Gui de Chauliac
80, avenue Augustin Fliche
34 295 Montpellier Cedex 5



Funder type : Drug company

[More informations](#)